The Food and Drug Administration approved Multaq [dronedarone], a heart treatment for atrial fibrillation and atrial flutter, that has been developed by Sanofi-Aventis SA. Multaq lowered hospitalization and death rates from heart-related problems by 24 percent, and it reduced the risk of ischemic and hemorrhagic stroke by 34 percent, in a study involving 4,628 patients with atrial fibrillation but not severe heart failure. FDA said the drug will come with a black box warning indicating that Multaq can cause death in people with recent severe heart failure and that alternative medication like amiodorone should be used.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지